Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
批准号:
8791785
负责人:
Rajesh Agarwal
金额:
$4.95万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-03-01 至 2017-01-31
关键词:
AnimalsApoptosisCancer EtiologyCell Cycle ArrestCell LineCellsChemopreventionChemopreventive AgentChronicClinicClinical ChemopreventionClinical TrialsClonal ExpansionCyclobutanesDNA DamageDNA RepairDNA-dependent protein kinaseDiagnosisE2F Transcription Factor 1E2F1 geneFoundationsFutureGeneticGenomeGrowth and Development functionHealthHepatoprotective AgentHumanIn VitroInbred HRS MiceIncidenceKineticsKnock-outLeadLinkMalignant NeoplasmsMeasuresMediatingMolecular TargetMusMutationNucleotide Excision RepairNucleotidesOutcomePathway interactionsPhosphorylationPreventionPreventiveProtein p53PyrimidineResearchRiskRoleSamplingSchemeSignal TransductionSkinSkin CancerSkin CarcinogenesisSkin CarcinomaSkin NeoplasmsSolar EnergySourceStreamSunlightSunscreening AgentsTP53 geneTestingThe SunTimeTopical applicationToxic effectTranscription-Coupled RepairTumor Suppressor GenesUltraviolet B RadiationUnited StatesWild Type Mousebasecancer chemopreventiondietary supplementsgenetic strainin vivoinnovationkeratinocytemouse modelnovelpreventprotective effectrepairedresponsesilibininskin cancer preventionultraviolet
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Skin cancer is the most common malignancy with more than 1 million new cases diagnosed annually in the United States alone. Solar UVB (ultraviolet B) radiation is the main etiologic factor for skin cancer; primarily, it causes DNA damages in skin epidermal cells which, if un-repaired, potentially lead to initiated cells. These initiated cells harbor mutations primarily in p53 tumor suppressor gene that eventually lead to their clonal expansion and formation of skin tumors. Sunscreens are used to protect against solar UVB radiation; however, due to high incidence of skin cancer, additional efforts continue for developing effective agents that could act against UVB-caused damages in normal skin, eventually leading to skin cancer chemoprevention. Our completed studies suggest that silibinin is one such agent that suppresses UVB-caused skin damages and prevents skin cancer in mouse model. We have also found that silibinin lowers UVB-caused DNA damage in terms of cyclobutane pyrimidine dimmer (CPD) positive cells and further enhances p53 protein level in mouse skin epidermal cell, and selectively increases E2F1 protein level in chronic UVB exposed mouse skin. Silibinin also enhances phosphorylation and accumulation of p53 in mouse keratinocyte JB6 cells in response to UVB. Our preliminary studies in p53-/- and wild-type SKH-1 hairless mice showed a decrease in UVB-induced CPD formation in skin by silibinin through enhanced DNA repair in a p53-dependent manner. Based on these completed novel and innovative studies, which have direct relevance to human skin cancer chemoprevention by silibinin, the major focus of this application is to further identify and establish molecular targets of silibinin efficacy in preventing skin cancer. The central hypothesis proposed is that silibinin reduces UVB-caused DNA damage by enhancing DNA repair via p53 and E2F1 resulting in chemoprevention of non-melanoma skin cancer. Specific aims are: I) to define and establish the role of p53 and E2F1 in silibinin-mediated epidermal DNA repair and prevention of skin carcinogenesis in response to UVB by using genetic approaches; II) to define and establish the role of upstream signal/s in p53- and E2F1-mediated DNA repair mechanisms of silibinin in response to UVB; and III) to examine and define the role of p53 and E2F1 in nucleotide excision repair-mediated DNA repair by silibinin in response to UVB. Human Health Relevance: The present proposal is highly relevant in establishing the preventive efficacy of silibinin against UVB-induced photodamage and photocarcinogenesis with highly novel and targeted mechanistic details. Overall, since solar radiation is the most common and un- avoidable source of skin cancer, we believe that the outcomes of the present proposal will benefit each and every human being 'under the sun'.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.
-
批准号:10220981
-
项目类别:
-
资助金额:$72.12万
-
财政年份:2020
-
负责人:Rajesh Agarwal
-
依托单位:
Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.
-
批准号:10472580
-
项目类别:
-
资助金额:$71.47万
-
财政年份:2020
-
负责人:Rajesh Agarwal
-
依托单位:
MicroRNAs in Skin Inflammation and Wounding by Mustard Vesicants.
-
批准号:9974481
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2019
-
负责人:Rajesh Agarwal
-
依托单位:
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
-
批准号:9326951
-
项目类别:
-
资助金额:$38.28万
-
财政年份:2014
-
负责人:Rajesh Agarwal
-
依托单位:
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
-
批准号:9128577
-
项目类别:
-
资助金额:$38.72万
-
财政年份:2014
-
负责人:Rajesh Agarwal
-
依托单位:
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
-
批准号:8629506
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2014
-
负责人:Rajesh Agarwal
-
依托单位:
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
-
批准号:9563978
-
项目类别:
-
资助金额:$38.26万
-
财政年份:2014
-
负责人:Rajesh Agarwal
-
依托单位:
Effective Therapies for Ocular Injuries by Vesicating Agents
-
批准号:8726411
-
项目类别:
-
资助金额:$74.69万
-
财政年份:2012
-
负责人:Rajesh Agarwal
-
依托单位:
Effective Therapies for Ocular Injuries by Vesicating Agents
-
批准号:8333167
-
项目类别:
-
资助金额:$75.45万
-
财政年份:2012
-
负责人:Rajesh Agarwal
-
依托单位:
Effective Therapies for Ocular Injuries by Vesicating Agents
-
批准号:9139458
-
项目类别:
-
资助金额:$73.55万
-
财政年份:2012
-
负责人:Rajesh Agarwal
-
依托单位:
Effective Therapies for Ocular Injuries by Vesicating Agents
-
批准号:8927642
-
项目类别:
-
资助金额:$74.23万
-
财政年份:2012
-
负责人:Rajesh Agarwal
-
依托单位:
Effective Therapies for Ocular Injuries by Vesicating Agents
-
批准号:8538399
-
项目类别:
-
资助金额:$75.08万
-
财政年份:2012
-
负责人:Rajesh Agarwal
-
依托单位:
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
-
批准号:10163671
-
项目类别:
-
资助金额:$36.93万
-
财政年份:2010
-
负责人:Rajesh Agarwal
-
依托单位:
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
-
批准号:8494116
-
项目类别:
-
资助金额:$3.75万
-
财政年份:2010
-
负责人:Rajesh Agarwal
-
依托单位:
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
-
批准号:8212513
-
项目类别:
-
资助金额:$30.37万
-
财政年份:2010
-
负责人:Rajesh Agarwal
-
依托单位:
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
-
批准号:9403428
-
项目类别:
-
资助金额:$36.93万
-
财政年份:2010
-
负责人:Rajesh Agarwal
-
依托单位:
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
-
批准号:7898374
-
项目类别:
-
资助金额:$31.34万
-
财政年份:2010
-
负责人:Rajesh Agarwal
-
依托单位:
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
-
批准号:8037077
-
项目类别:
-
资助金额:$30.37万
-
财政年份:2010
-
负责人:Rajesh Agarwal
-
依托单位:
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
-
批准号:8606326
-
项目类别:
-
资助金额:$4.8万
-
财政年份:2010
-
负责人:Rajesh Agarwal
-
依托单位:
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
-
批准号:10287350
-
项目类别:
-
资助金额:$15.55万
-
财政年份:2010
-
负责人:Rajesh Agarwal
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: